On July 21, 2016 Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, reported that the first patient has been enrolled into the Phase 2 portion of the PAZOFOS Study (Press release, Mateon Therapeutics, JUL 21, 2016, View Source [SID:1234513984]). The PAZOFOS Study is a Phase 1b/2 clinical trial in patients with recurrent ovarian cancer that will assess the efficacy and safety of the combination of Mateon’s investigational drug CA4P plus Novartis’ approved tyrosine kinase inhibitor pazopanib (Votrient) compared to pazopanib alone. The primary outcome measure of the Phase 2 portion of the study is progression free survival measured by RECIST; secondary endpoints include safety, overall survival, objective response rate and relevant biomarkers. The study is designed to enroll 128 patients at ten sites in the United Kingdom. Schedule your 30 min Free 1stOncology Demo! "The advancement of the PAZOFOS Study into the Phase 2 portion is an important milestone for the continued development of CA4P," stated William D. Schwieterman, M.D., President and Chief Executive Officer of Mateon. "There are a number of parallels between the PAZOFOS Study and the completed GOG-0186I Study, each in recurrent ovarian cancer and evaluating CA4P in combination with an established anti-angiogenic agent. We believe combination vascular targeted therapy with a VDA and an anti-angiogenic has the potential to be a powerful approach to fight cancer, and we look forward to receiving data on this trial as it becomes available."
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
PAZOFOS is sponsored by The Christie NHS Foundation Trust and coordinated by the Manchester Academic Health Science Centre, Trials Coordination Unit (MAHSC-CTU) with additional support from The University of Manchester, the Royal Marsden NHS Foundation Trust and Mount Vernon Cancer Centre (portion of the East and North Hertfordshire NHS Trust). CA4P and pazopanib are being provided by Mateon and Novartis, respectively.